Phase 4 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The participant, or their legal representative, must be willing and able to provide written consent before any study procedures begin.
- A confirmed diagnosis of prostate adenocarcinoma (a type of prostate cancer) is required, confirmed through tissue testing or a combination of imaging and blood marker results.
- Participants must be male and aged 18 or older. People of all racial and ethnic backgrounds are welcome.
- Cancer must show up on an initial PSMA PET scan (a specialised imaging scan that detects prostate cancer cells).
- Participants must be planned to start hormonal therapy within eight weeks of the initial PSMA PET scan. The specific type of hormonal therapy depends on which group applies (confirm with trial site).
- A life expectancy of more than 3 months is required.
- Group 1 (Castration-resistant prostate cancer): Cancer that has continued to grow despite hormone-lowering treatment, with a rising PSA level confirmed by two tests at least one week apart, very low testosterone levels (below 50 ng/dL), continuous hormone-suppressing treatment for at least 4 months, and no use of certain advanced hormone-blocking medications in the past 4 months.
- Group 2 (Castration-sensitive prostate cancer): Cancer that still responds to hormone-lowering treatment, with testosterone above 50 ng/dL, and no use of hormone-suppressing or advanced hormone-blocking medications in the past 12 months.
Who may not be able to join:
- People with a serious, uncontrolled infection.
- People with another illness or condition that would make it difficult to follow the study requirements.
- People who receive any cancer treatment other than the planned hormonal therapy (including radiation or other systemic treatments), or who start any supplements or herbal products intended to treat cancer, between the first PSMA PET scan and the follow-up PSMA PET scan at day 28.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nadine Mallak, MD, OHSU Knight Cancer Institute
Phone: 503-494-4960
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in maximum standardized uptake value (SUVmax) on post-therapy initiation PSMA PET (8 ± 2 days) compared to baseline.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.